STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3779-3787

  Pietras, Kristian ^a   Stumm, Michael ^b   Hubert, Martine ^c   Buchdunger, Elisabeth ^b   Rubin, Kristofer ^d   Heldin, Carl Henrik ^a   McSheehy, Paul ^b   Wartmann, Markus ^b   Östman, Arne ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS PHARMA K K   (Japan)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPOTHILONE B; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; INTERSTITIAL HYPERTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; THYROID CARCINOMA; TUMOR GROWTH; TUMOR INTERSTITIAL FLUID PRESSURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; EPOTHILONES; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PIPERAZINES; PYRIMIDINES; THYROID NEOPLASMS; TIME FACTORS;

EID: 0141567995     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev., 26: 71-90, 1997.
2. Brekken, C., Hjelstuen, M. H., Bruland, S., and de Lange Davies, C. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res., 20: 3513-3519, 2000.
3. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., and Boucher, Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res., 60: 5565-5570, 2000.
4. Netti, P. A., Hamberg, L. M., Babich, J. W., Kierstead, D., Graham, W., Hunter, G. J., Wolf, G. L., Fischman, A., Boucher, Y., and Jain, R. K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA, 96: 3137-3142, 1999.
5. Pietras, K., Östman, A., Sjoquist, M., Buchdunger, E., Reed, R. K., Heldin, C-H., and Rubin, K. Inhibition of Platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res., 61: 2929-2934, 2001.
6. Pietras, K., Rubin, K., Sjoblom, T., Buchdunger, E., Sjoquist, M., Heldin, C-H., and Ostman, A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res., 62: 5476-5484, 2002.
7. 1 is paralleled by an increased uptake of (51)Cr-EDTA. Int. J. Cancer, 86: 636-643, 2000.
8. Emerich, D. F., Snodgrass, P., Dean, R. L., Lafreniere, D., Agostino, M., Wiens, T., Xiong, H., Hasler, B., Marsh, J., Pink, M., Kim, B. S., and Bartus, R. T. Bradykinin modulation of tumor vasculature. I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy. J. Pharmacol. Exp. Ther., 296: 623-631, 2001.
9. Heldin, C. H., and Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev., 79: 1283-1316, 1999.
10. Forsberg, K., Valyi-Nagy, I., Heldin, C-H., Herlyn, M., and Westermark, B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. USA, 90: 393-397, 1993.
11. Skobe, M., and Fusenig, N. E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. USA, 95: 1050-1055, 1998.
12. Shao, Z. M., Nguyen, M., and Barsky, S. H. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene, 19: 4337-4345, 2000.
13. Ostman, A., and Heldin, C-H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res., 80: 1-38, 2001.
14. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
15. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., and Lydon, N. B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 295: 139-145, 2000.
16. Okuda, K., Weisberg, E., Gilliland, D. G., and Griffin, J. D. ARG tyrosine kinase activity is inhibited by STI571. Blood, 97: 2440-2448, 2001.
17. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
18. van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., Silberman, S., and Nielsen, O. S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet, 358: 1421-1423, 2001.
19. Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., Dimitrijevic, S., Mahon, F. X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N. C., and Goldman, J. M. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med., 347: 481-487, 2002.
20. Rubin, B. P., Schuetze, S. M., Eary, J. F., Norwood, T. H., Mirza, S., Conrad, E. U., and Bruckner, J. D. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol., 20: 3586-3591, 2002.
21. Altmann, K. H., Wartmann, M., and O'Reilly, T. Epothilones and related structures: a new class of microtubule inhibitors with potent in vivo antitumor activity, Biochim. Biophys. Acta, 1470: M79-M91, 2000.
22. Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E., and Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res., 55: 2325-2333, 1995.
23. Ain, K. B., Tofiq, S., and Taylor, K. D. Antineoplastic activity of Taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J. Clin. Endocrinol. Metab., 81: 3650-3653, 1996.
24. United Kingdom Coordinating Committee on Cancer Research (UKCCCR). Guidelines for the welfare of animals in experimental neoplasia (Ed. 2). Br. J. Cancer, 77: 1-10, 1998.
25. Wiig, H., Tveit, E., Hultborn, R., Reed, R. K., and Weiss, L. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand. J. Clin. Lab. Investig., 42: 159-164, 1982.
26. Sjöblom, T., Shimizu, A., O'Brien, K. P., Pietras, K., Dal Cin, P., Buchdunger, E., Dumanski, J. P., Östman, A., and Heldin C-H. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res., 61: 5778-5783, 2001.
27. Conway, E. M., Collen, D., and Carmeliet, P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res., 49: 507-521, 2001.
28. Sundberg, C., Ljungström, M., Lindmark, G., Gerdin, B., and Rubin, K. Microvascular pericytes express platelet-derived growth factor β receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol., 143: 1377-1388, 1993.
29. Sundberg, C., Branting, M., Gerdin, B., and Rubin, K. Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma: transfer of platelet-derived growth factor-AB/BB to stromal cells. Am. J. Pathol., 151: 479-492, 1997.
30. Rodt, S. Å., Åhlén, K., Berg, A., Rubin, K., and Reed, R. K. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. (Lond.), 495: 193-200, 1996.
31. Heuchel, R., Berg, A., Tallquist, M., Ahlen, K., Reed, R. K., Rubin, K., Claesson-Welsh, L., Heldin, C. H., and Soriano, P. Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl. Acad. Sci. USA, 96: 11410-11415, 1999.